When broken down by biomarker status, the 5-year overall survival for the Newfoundland and Labrador cohort for hormone-receptor-positive, HER2+, and triple-negative breast cancers was 88.7%, 87.5%, and 70.0%, respectively, reflecting worse outcomes for more aggressive disease pathologies as anticipated. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.